BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Science in Boston - ECPv6.18.3.1//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Science in Boston
X-ORIGINAL-URL:https://scienceinboston.com
X-WR-CALDESC:Events for Science in Boston
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:America/New_York
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20180311T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20181104T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20190310T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20191103T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20200308T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20201101T060000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20191010T173000
DTEND;TZID=America/New_York:20191010T193000
DTSTAMP:20190909T151301Z
CREATED:20190909T151301Z
LAST-MODIFIED:20190909T151301Z
UID:6451-1570728600-1570735800@scienceinboston.com
SUMMARY:Whitehead Connects with John Maraganore\, PhD
DESCRIPTION:Description\nJoin us on Thursday\, October 10 for Bringing RNAi From Basic Science to Patients presented by Dr. John Maraganore who has served as CEO and Director of Alnylam since 2002. \nPrior to Alnylam\, Dr. Maraganore served as an officer and a member of the management team for Millennium Pharmaceuticals\, Inc. \nAs Senior Vice President: Strategic Product Development for Millennium\, he was responsible for the company’s product franchises in oncology\, and cardiovascular\, inflammatory\, and metabolic diseases. He was previously Vice President: Strategic Planning and M&A and\, prior to that\, he was General Manager of Millennium BioTherapeutics\, Inc.\, a former subsidiary of Millennium. \nBefore Millennium he served as Director of Molecular Biology and Director of Market and Business Development at Biogen\, Inc. At Biogen\, Dr. Maraganore invented and led the discovery and development of ANGIOMAX® (bivalirudin) for injection\, formerly HIRULOGTM and currently marketed by The Medicines Company. Prior to Biogen\, Dr. Maraganore was a scientist at ZymoGenetics\, Inc.\, and the Upjohn Company. \nDr. Maraganore received his MS and PhD in biochemistry and molecular biology at the University of Chicago. He is a Director for Agios Pharmaceuticals. Dr. Maraganore is the former Chair of the Biotechnology Industry Organization (BIO) Board\, and is a member of the BIO Executive Committee.
URL:https://scienceinboston.com/event/whitehead-connects-with-john-maraganore-phd/
LOCATION:Whitehead Institute for Biomedical Research\, 455 Main Street\, Cambridge\, MA\, 02142\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20191010T173000
DTEND;TZID=America/New_York:20191010T193000
DTSTAMP:20190909T151301Z
CREATED:20190909T151301Z
LAST-MODIFIED:20190909T151301Z
UID:27338-1570728600-1570735800@scienceinboston.com
SUMMARY:Whitehead Connects with John Maraganore\, PhD
DESCRIPTION:Description\nJoin us on Thursday\, October 10 for Bringing RNAi From Basic Science to Patients presented by Dr. John Maraganore who has served as CEO and Director of Alnylam since 2002. \nPrior to Alnylam\, Dr. Maraganore served as an officer and a member of the management team for Millennium Pharmaceuticals\, Inc. \nAs Senior Vice President: Strategic Product Development for Millennium\, he was responsible for the company’s product franchises in oncology\, and cardiovascular\, inflammatory\, and metabolic diseases. He was previously Vice President: Strategic Planning and M&A and\, prior to that\, he was General Manager of Millennium BioTherapeutics\, Inc.\, a former subsidiary of Millennium. \nBefore Millennium he served as Director of Molecular Biology and Director of Market and Business Development at Biogen\, Inc. At Biogen\, Dr. Maraganore invented and led the discovery and development of ANGIOMAX® (bivalirudin) for injection\, formerly HIRULOGTM and currently marketed by The Medicines Company. Prior to Biogen\, Dr. Maraganore was a scientist at ZymoGenetics\, Inc.\, and the Upjohn Company. \nDr. Maraganore received his MS and PhD in biochemistry and molecular biology at the University of Chicago. He is a Director for Agios Pharmaceuticals. Dr. Maraganore is the former Chair of the Biotechnology Industry Organization (BIO) Board\, and is a member of the BIO Executive Committee.
URL:https://scienceinboston.com/event/whitehead-connects-with-john-maraganore-phd-2/
LOCATION:Whitehead Institute for Biomedical Research\, 455 Main Street\, Cambridge\, MA\, 02142\, United States
END:VEVENT
END:VCALENDAR